SOBI — Swedish Orphan Biovitrum AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK165.02bn
- SEK180.18bn
- SEK28.24bn
Brief: SOBI 2025 Revenue, EBITA Margin Exceed Outlook
Brief: Sobi To Advance Gamifant® (Emapalumab) In IDS Based On Embrace Topline Data
Brief: Sobi to Acquire Arthrosi Therapeutics to Boost Gout Treatment Pipeline
Sweden's Sobi to buy US biotech Arthrosi for up to $1.5 billion to boost gout pipeline (updated)
Sweden's SOBI to buy Arthrosi Therapeutics for $1.5 billion
Brief: SOBI Says Co To Acquire Arthrosi Therapeutics For $1.5 billion
Brief: EMA's CHMP Recommended Granting Marketing Authorisation For Moderna's Mnexspike
Brief: SOBI Gets Positive CHMP Opinion For Aspaveli
Europe Research Roundup: Applied Nutrition, Noba Bank Group, Trainline
Top of the Street: Hermes, Moncler, SOBI, Capgemini
Brief: Swedish Orphan Biovitrum Executive Sells Shares In Company
Brief: Swedish Orphan Biovitrum Executive Disposes SEK 18.9 Mln Worth Of Co Share
Brief: Swedish Orphan Biovitrum CEO Disposes SEK 26.0 Mln Worth Of Co Share
Brief: SOBI Senior Executive Sold SEK 37.1 Mln Worth Of Co Share
Brief: Swedish Orphan Biovitrum Executive Sells SEK 32.2 Mln Worth Of Co's Share
Brief: SOBI Q3 Net Income SEK -2,895 Million
Brief: SOBI Q3 EBIT SEK -3,858 Million Vs. IBES Estimate SEK 2,404 Million
Brief: SOBI Announces Revised Full Year Outlook And Advances Publication Of The Q3 2025 Financial Report
Brief: SOBI: Tryngolza (Olezarsen) Approved In EU For Familial Chylomicronemia Syndrome